- Home
- BIIB vs FUTU Comparison
BIIB vs FUTU Comparison
Compare BIIB & FUTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIIB | FUTU |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 23.0B |
| IPO Year | 1991 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BIIB | FUTU |
|---|---|---|
| Price | $196.52 | $146.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 5 |
| Target Price | $195.13 | ★ $208.60 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 02-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 119.17 |
| EPS | 8.79 | ★ 8.95 |
| Revenue | ★ $9,890,600,000.00 | $2,442,834,991.00 |
| Revenue This Year | N/A | $85.76 |
| Revenue Next Year | N/A | $14.66 |
| P/E Ratio | $22.36 | ★ $16.40 |
| Revenue Growth | 2.22 | ★ 87.15 |
| 52 Week Low | $110.04 | $70.60 |
| 52 Week High | $202.41 | $202.53 |
Technical Indicators
Market Signals| Indicator | BIIB | FUTU |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 33.14 |
| Support Level | $187.20 | $147.14 |
| Resistance Level | $202.41 | $160.90 |
| Average True Range (ATR) | 6.19 | 5.84 |
| MACD | 1.76 | -1.17 |
| Stochastic Oscillator | 81.34 | 11.09 |
Price Performance
Historical ComparisonAbout BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.